Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2017-10-04 Director's Dealing
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains the header 'DGAP-DD: MorphoSys AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. This content directly corresponds to the definition of Director's Dealing reports, which track personal share transactions by executives. This matches the filing type code DIRS.
2017-10-04 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'MorphoSys AG: Release according to Article 26a of the WpHG' and specifically announces the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This type of announcement, dealing with changes in the total number of shares/voting rights, falls under capital structure changes. While it relates to capital, the specific focus on the total voting rights count and the regulatory context (WpHG Article 26a) suggests a notification about the capital structure. The closest fit among the provided definitions is 'Share Issue/Capital Change' (SHA), as a conditional capital increase directly impacts the share count. It is not a general financing update (CAP) but a specific notification about the resulting share count.
2017-09-29 English
MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients (news with additional features)
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "Media Release" and begins with a date and a headline announcing clinical study results for a drug candidate (MOR106). It contains key highlights, safety data, efficacy observations, and quotes from management and advisors regarding the Phase 1 study results. The document structure, including the DGAP-News header and the explicit mention of 'News Details' and 'Corporate | 27 September 2017 07:30', strongly indicates this is an initial announcement of financial/operational results, not a comprehensive report (like 10-K or IR) or a transcript (CT). Since it details the initial announcement of periodical financial/study results, the most appropriate classification is Earnings Release (ER), even though it pertains to clinical trial milestones rather than revenue/profit figures, as it serves the function of an initial results disclosure to the market. It is not a formal regulatory filing like 10-K, nor is it a presentation (IP) or a call transcript (CT).
2017-09-27 English
MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with TremfyaTM (Guselkumab) in Psoriatic Arthritis (news with additional features)
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "Media Release" and begins with a date and a headline announcing a corporate event (initiation of Phase 3 studies by a licensee). It contains standard press release formatting, including contact information, boilerplate company descriptions, and is disseminated via DGAP, which handles 'Financial/Corporate News and Press Releases'. This structure strongly indicates a general corporate announcement rather than a specific regulatory filing like a 10-K, an Earnings Release (ER), or a detailed Interim Report (IR). Since it is a general corporate news release announcing business progress, and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate general category for corporate news dissemination that isn't a primary financial report is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements and press releases not covered elsewhere.
2017-09-21 English
MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya(TM) (Guselkumab) Recommending Approval in Europe (news with additional features)
Regulatory Filings Classification · 100% confidence The document is titled 'Media Release' and is dated September 18, 2017. It announces a positive opinion from the CHMP for a drug developed by MorphoSys's licensee, Janssen. The text explicitly states it is a 'News Details' item disseminated by DGAP, which handles 'Regulatory Announcements, Financial/Corporate News and Press Releases.' Since this is a specific, non-periodic announcement about a regulatory/clinical development milestone (CHMP opinion) and not a comprehensive financial report (like 10-K or IR), nor a management change (MANG) or dividend notice (DIV), it falls best under the general category for regulatory announcements that aren't covered by more specific codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news release about a regulatory event, although it is not a formal SEC filing. It is not an Earnings Release (ER) as it discusses clinical/regulatory progress, not financial results.
2017-09-18 English
MorphoSys Presents Vision for Growth at its Capital Markets Day (news with additional features)
Investor Presentation Classification · 98% confidence The document is titled "MorphoSys Presents Vision for Growth at its Capital Markets Day" and explicitly states that the Management updated analysts and investors on the Company’s growth and development strategy. A Capital Markets Day (CMD) is an event specifically designed for investors to present strategy, pipeline updates, and financial outlook, which aligns perfectly with the definition of an Investor Presentation (IP). Although it is presented as a news release (DGAP-News), the core content is the presentation material and strategy review from the CMD, not a brief announcement of a report (RPA) or a general regulatory filing (RNS). It is a detailed presentation of strategy and pipeline progress.
2017-09-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.